Fig 1.

DZnep treatment inhibits PRC2 catalytic activity and decreases EZH2 protein levels in THP1 monocytes. Whole-cell lysates were prepared from THP1 monocytes treated with 5 μM DZnep, 0.2 μM PMA, or DMSO for 3 days. (A) Western blot analysis of H3K27me3 and H3K36me3. Total H3 served as a loading control. (B) Western blot analysis of PRC2 components EZH2 and SUZ12 and of the chromatin binding protein HP1. Actin served as a loading control. (C) Fluorescence microscopy of THP1 cells, treated as indicated, following FDA or PI staining for viability. (D) Bright-field microscopy of morphological changes of THP1 cells, treated as indicated. (E) CD11b/MAC-1 expression on the surfaces of THP1 cells, treated as indicated.